Targeting the RB tumor suppressor in breast cancer treatment
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10798148
This study is looking at how changes in a specific cancer-fighting pathway affect the treatment of estrogen receptor-positive metastatic breast cancer, with the goal of finding better ways to overcome resistance to common therapies and improve outcomes for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10798148 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the RB tumor suppressor pathway in the treatment of estrogen receptor-positive (ER+) metastatic breast cancer. It aims to understand how disruptions in this pathway contribute to resistance against common therapies, such as endocrine treatments and CDK4/6 inhibitors. By analyzing the mechanisms of resistance and exploring new therapeutic strategies, the research seeks to improve treatment outcomes for patients with this type of breast cancer. The approach includes drug screening and the use of organoid models to identify effective treatment regimens.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with estrogen receptor-positive metastatic breast cancer, especially those experiencing treatment resistance.
Not a fit: Patients with non-ER+ breast cancer or those who are not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with ER+ breast cancer, particularly those who have developed resistance to current treatments.
How similar studies have performed: Previous research has shown promising results in targeting cell cycle pathways in cancer treatment, indicating that this approach may be effective.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KNUDSEN, ERIK — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: KNUDSEN, ERIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers, neoplasm/cancer